Loading…
Loading…
Avino Silver (ASM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ASM International should exceed its 2027 sales forecast, its chief executive said on Wednesday, though strained supply chain could limit how far revenue rises above the target.
ASM International forecast on Tuesday fourth-quarter revenue above expectations and said it would reach its 2030 sales target three years early, driven by AI-related capacity investments.
The Dutch group said revenue next year should exceed $6.37 billion as companies invest heavily in chips to keep up with soaring demand for artificial intelligence.
Almere, The NetherlandsOctober 27, 2026, 6 p.m. CET Record quarter on leading-edge growth; 2027 revenue outlook above €5.7 billion ASM International N.V.
Putting Fujitsu's cyber defense strategy into practice to support management decision-making and frontline responseKAWASAKI, Japan, Oct 27, 2026 - (JCN Newswire
Publication of first ever head-to-head comparison of gut microbiome changes associated with novel oral preclinical PolC (pol IIIC*) inhibitors to linezolid in a murine neutropenic thigh infection model Structural molecular modification of molecules related to ibezapolstat (IBZ) improved solubility and systemic exposure of novel Pol IIIC inhibitors with all three tested Pol IIIC inhibitors reduced MRSA burden in a neutropenic mouse thigh model Pol IIIC inhibitors in this study maintained high gut microbial diversity, as well as preserved microbiome metabolic function, in contrast to the marked disruption shown by linezolid Pol IIIC inhibitor compounds specifically preserved anaerobic microbiome components and metabolism, whereas linezolid induced depletion and disruption of healthy anaerobic bacterial communities Acurx's DNA pol IIIC inhibitor preclinical product candidates are FDA QIDP and Fast-Track eligible and target Gram-positive infections classified as Serious Threat priorities by CDC STATEN ISLAND, N.Y., Oct. 21, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for serious and life-threatening bacterial infections, today announced publication in the ASM (American Society for Microbiology) Microbiology Spectrum journal of results of a study entitled: The effects of novel oral preclinical PolC inhibitor antibiotic candidates on the gut microbiome in a murine thigh infection model.
Avino Silver (ASM) concluded the recent trading session at $5.31, signifying a +2.22% move from its prior day's close.